Live Webinar SaaS Valuations in 2026: Public and Private Markets Update Tue, Nov 17 11am ET / 5pm CET Register

Testing Laboratory Valuations: EV/EBITDA and EV/Revenue

Testing laboratories compared: the multiples buyers pay for food, environmental, pharmaceutical, EMC, calibration and materials labs, and who is acquiring them.

Marcin Majewski
Published October 13, 2026 · 12 min read · Connect on LinkedIn

Knowing what your testing laboratory is worth matters most on one particular day: the day you decide to sell the business you spent years building, sample by sample and accreditation by accreditation. What it fetches on that day depends on how many credible buyers compete for it, and for laboratories there are many: 303 different buyers have bought testing laboratories since 2015. The sections below lay out the public record behind those acquisitions: the multiples for each kind of laboratory, how they compare with inspection and certification, and the groups doing the buying.

Laboratory ownership is fragmented, and it is consolidating: the pace of acquisitions has picked up, from an average of 86 deals a year in 2015 to 2020 to 130 a year in 2023 to 2025, so a well-run laboratory can draw several buyers into a sale.

In short, testing laboratory deals with a disclosed multiple have a median of about 10.1x EBITDA and 2.4x revenue. On EBITDA that is a little above the median for all TIC deals on our pages, 9.9x (54 deals). On revenue, laboratories sell higher: 2.4x against 1.8x (142 deals).

Testing Laboratories Compared With Inspection and the Wider TIC Market

Of the 1,271 laboratory deals in our database, 128 disclose a value, 72 disclose enough to calculate an EV/Revenue multiple and 24 an EV/EBITDA multiple. The 24 are mostly larger deals, with a median deal size of about $60M, so a smaller laboratory should expect to sell below the medians shown unless several buyers compete for it and it can show a broad accreditation scope and recurring, regulated samples. The interquartile range shows how far individual deals sit from the median.

Testing laboratoriesInspectionCertificationAll TIC (our three hubs)
Deals since 20151,2711,3761942,841
Median EV/EBITDA10.1x (24 deals)9.5x (25 deals)11.8x (5 deals)9.9x (54 deals)
Interquartile range, EV/EBITDA8.0x to 12.9x7.5x to 11.5xToo few deals (5) for a range8.0x to 12.5x
Median EV/Revenue2.4x (72 deals)1.6x (63 deals)2.0x (7 deals)1.8x (142 deals)
Median deal size (EV where disclosed, otherwise the disclosed deal value)$13.4M (128 deals)$15.0M (127 deals)$6.7M (27 deals)$13.4M (282 deals)
Share of deals by private equity buyers42%60%41%50%
Source: Aventis Advisors TIC deal database.
Larger TIC deals carry higher EBITDA multiplesMedian EV/EBITDA by deal size, all TIC deals with a published multiple, since 20150x5x10x15x8.0xUnder $50M21 deals9.1x$50M to $100M10 deals11.5x$100M to $500M11 deals12.2x$500M and over11 dealsTesting laboratories 10.1x (24 deals)All TIC deals, median EV/EBITDATesting laboratories 10.1x median
Source: Aventis Advisors TIC deal database.

In EBITDA terms, the first band covers firms with up to about $6M of EBITDA.

We track every testing laboratory acquisition since 2015, 1,271 deals by 303 different buyers, so we know which buyers fit a laboratory like yours and what they have paid.

What is your laboratory worth?

Send us three numbers: revenue, EBITDA and revenue growth rate. Within two working days we show you in confidence how your laboratory measures up against 1,271 testing laboratory deals, which buyer groups have acquired laboratories like yours, and how any offer you hold compares with what they paid where terms are published.

Request your valuation assessment or email the numbers to marcin.majewski@aventis-advisors.com.

Testing Laboratory Segments

The table splits the deals by the kind of laboratory, each target classified by its main business. Each linked row has its own page with multiples, value drivers and buyers.

LaboratoryDeals since 2015Since 2021Private equity shareMedian deal sizeMedian EV/Revenue
Food and agricultural testing30215528%$16.6M (20 deals)2.0x (14 deals)
Environmental, water and asbestos testing25515937%$23.4M (17 deals)1.7x (8 deals)
Calibration18712669%$9.1M (22 deals)2.2x (10 deals)
Pharmaceutical and medical device testing1719853%$13.2M (19 deals)2.5x (12 deals)
EMC and product safety testing1347926%$16.7M (25 deals)2.8x (11 deals)
Materials testing1267447%$41.0M (14 deals)2.4x (10 deals)
Consumer product testing573623%$13.2M (7 deals)3.2x (3 deals)
Construction materials testing392859%$11.5M (4 deals)1.8x (4 deals)
Source: Aventis Advisors TIC deal database.

Calibration laboratories draw the most private equity buying: platforms made 69% of the deals, and 75% of those since 2021. Food and agricultural laboratories are the largest group by deal count and mostly sell to trade buyers, with private equity buyers at 28%. Revenue multiples run from 1.7x for environmental, water and asbestos laboratories to 2.8x for EMC and product safety laboratories, and materials testing has the largest median deal, at $41.0M, from 14 disclosed values that include the sale of several whole laboratory groups.

What Drives a Testing Laboratory Valuation

A buyer works through each of these in due diligence, and each one moves a laboratory up or down the range. Several of them take a year or more to change, so the time to start is well before a sale.

Accreditation scope

ISO/IEC 17025 accreditation, and the approvals that sit on top of it, such as GMP for pharmaceutical testing or regulator listings for drinking water and food, decide which samples a laboratory may test and report. A buyer reads the scope method by method, because a broad, current scope takes years for a competitor to build. Keep the full schedule of accredited methods, the last assessment reports and any open findings ready to share.

Recurring, regulated samples

Drinking water compliance, food safety programs, pharmaceutical batch release and calibration intervals send samples on a fixed cycle. Buyers pay more for revenue tied to these cycles than for one-off project work. Show how much of your revenue comes from customers on regular testing programs, and for how many years they have stayed.

Instrument capacity and turnaround

A laboratory earns from how fully its instruments and analysts are used. Spare capacity lets a buyer add its own customers’ samples, while ageing instruments mean spending after the deal. Show utilization by instrument group, the age of the main equipment and your turnaround times against what customers are promised.

Technical staff

Accreditation names the people who can authorize results, and customers often follow a trusted laboratory manager. A laboratory where the owner signs most reports carries key-person risk. A team of qualified analysts with documented competence and a deputy for each technical role supports the price.

Customer and end-market mix

Buyers discount dependence on one large customer or one cyclical industry and pay for a spread across regulated end markets. Set out the share of revenue from your ten largest customers and from each end market over the last three years.

Size and position in a network

Smaller laboratories are usually bought as add-ons by groups that already run laboratories nearby, at lower multiples, because the buyer takes on integration and moves samples between sites. A laboratory with a strong regional position, or a method a group lacks, negotiates from a stronger place.

How we present these to buyers. A buyer pays for what it can see and check. Part of our work in a sale is to present the business as strongly as the facts allow: we set out the accreditation scope, show how much of the sample flow is regulated and repeats, and document the technical team behind the signatures, and we deal with weak points before a buyer finds them and uses them to lower the offer. A valuation assessment is the place to start, a year or two before a sale.

Who Is Buying Testing Laboratories

We count 1,271 acquisitions of testing laboratories since January 2015, by 303 different buyers. Private equity firms and their platforms made 42% of them. Their share has risen from 33% of the 516 deals in 2015 to 2020 to 48% of the 755 deals since 2021. The targets were in 58 countries.

The five buyers in the table made 427 of these deals, about a third. Eurofins Scientific, SGS and ALS Limited are listed groups that buy across most kinds of laboratory. Every laboratory Trescal has bought is a calibration laboratory, and Tentamus Group buys mostly food and pharmaceutical laboratories.

BuyerHeadquartersOwnershipTesting laboratory dealsOther TIC dealsTotal TIC deals
Eurofins Scientific logoEurofins ScientificLuxembourgListed20537242
Trescal logoTrescalFrancePE-backed652994
Tentamus Group logoTentamus GroupGermanyPE-backed (BC Partners since 2021)62769
SGS logoSGSSwitzerlandListed6156117
ALS logoALS LimitedAustraliaListed34236
Source: Aventis Advisors TIC deal database.

A buyer that approaches you is most likely a laboratory group that already runs laboratories in your region or your kind of testing, or a private equity-backed platform adding sites. A group buying capacity, methods or a location for its network and a platform building a business it plans to sell again will price and structure an offer differently; see strategic vs financial buyers.

Deals per year, and the private equity shareTesting laboratory acquisitions since 2015025507510012515078201528%85201625%100201734%104201836%85201938%64202036%135202150%149202239%120202344%144202449%125202553%822026*59%PEColumns: deals per year (2021 on in purple). *2026: January to October.PE row: share of deals made by private equity firms and the platforms they back.
Source: Aventis Advisors TIC deal database.
Where the laboratories bought were basedTesting laboratory acquisitions by target region, since 2015Continental Europe450 (35%)North America432 (34%)Asia-Pacific172 (14%)UK and Ireland126 (10%)Latin America66 (5%)Middle East and Africa25 (2%)
Source: Aventis Advisors TIC deal database.

One buyer’s offer tells you what that buyer would like to pay. Offers from several buyers, made at the same time on the same information, tell you what the business is worth. That is what a sale process does, and it is the work we do for owners: talk to us before you reply to an approach.

Selling a Testing Laboratory: What a Run Process Changes

An approach usually comes on the buyer’s timetable, on the buyer’s terms and as the only offer on the table, so an owner who answers it alone is negotiating with one party. A competitive sale process changes that in four ways, and running it is what we do for owners.

Several buyers bid at the same time. Since 2015, 303 different buyers have bought testing laboratories, and private equity-backed buyers made 48% of the deals since 2021. A laboratory group with sites nearby and a platform entering your region value the same laboratory differently, and offers made in the same week, on the same information, show what the market will pay.

The process sets the terms of engagement. The seller sets the timetable, the information each buyer sees and the date offers are due, so competition between buyers sets the value.

Every term is negotiated while alternatives exist. The cash paid at closing, any earn-out and what it measures, and the roles of you and your laboratory managers after the sale all move most while a second buyer is still in the process.

The business is ready before the first call. Your accreditation schedule and assessment reports, competence records for your signatories, revenue by customer and end market, instrument utilization and age, and your main testing contracts. We prepare all of it with you before any buyer is contacted.

Why Laboratory Owners Work With Us

We advise owners on sales with typical enterprise values between $5M and $100M, as partners of the Globalscope network. We also advise serial acquirers, which is how we know the way their offers are built and where they leave room.

Recent transactions:

  • Advice to Apave on its acquisitions of ISOCERT and De Duurzame Adviseurs.
  • Sale of CKSource, the rich-text editor developer, to PSG via Tiugo Technologies, after a global process that drew several letters of intent.
  • Advice to Visma on its acquisition of SaldeoSMART.

“We were impressed with Marcin’s negotiating skills and Aventis’ ability to make things happen.”

Sindre Talleraas Holen, M&A Director, Visma

“Aventis Advisors did the heavy lifting so that our management team could stay focused on our business.”

Wiktor Walc, President, CKSource

Before you reply to a buyer

Send us three numbers: revenue, EBITDA and revenue growth rate. Within two working days we show you in confidence how your laboratory measures up against 1,271 testing laboratory deals, which buyer groups have acquired laboratories like yours, and how any offer you hold compares with what they paid where terms are published.

Request your valuation assessment

Talk to Us

Has a buyer been in touch about your testing laboratory? Talk to us before you reply, agree a price or sign a letter of intent. We run competitive sale processes for owners: we prepare the business, approach the laboratory groups and private equity platforms most likely to pay for your accreditation scope, people and testing programs, bring their offers to a single deadline and negotiate through to closing. Aventis Advisors is a boutique M&A firm advising on transactions with typical enterprise values between $5M and $100M. Write to us at marcin.majewski@aventis-advisors.com. The first conversation is confidential. For more on how we work, see our M&A advisory for TIC companies.

Methodology

The figures cover majority acquisitions of companies whose main business is testing samples or products in their own laboratories, worldwide, since January 2015. Laboratories that collect their own samples for testing are counted. Firms whose main work is at the customer’s site are covered on our inspection company valuation pages and certification bodies on our certification body valuation page; equipment makers, software providers, contract research organizations, clinical laboratories and consultancies are excluded.

The deals come from the Aventis Advisors TIC deal database, which combines Mergermarket with acquirer announcements and our own research. EV/EBITDA and EV/Revenue use enterprise value (EV), which is equity value plus net debt; EBITDA is earnings before interest, tax, depreciation and amortization. Median deal size uses EV where disclosed, otherwise the disclosed deal value, which is the consideration for the stake acquired; stakes of 51% to 99% count only where an EV is stated. Distressed sales, and multiples outside 1x to 60x EBITDA or 0.05x to 20x revenue, are excluded from the multiples. Most private deals close at undisclosed values, so the deals with a published figure are a small sample. A median from as few as two deals is shown only where it falls inside the interquartile range of the next wider group, such as all testing laboratories; otherwise the page points to that group. Ranges need at least ten deals. EV/EBITDA is shown where the multiple or the EBITDA was published by the buyer, the seller, filings or a reputable data source; EBITDA derived from a stated margin is excluded. Each deal is counted under the buyer’s group at the time of the deal, and private equity buyers are private equity firms and the companies they owned then. All TIC combines the inspection, testing laboratory and certification deals on our pages, 2,841 since 2015.

Marcin Majewski

Founder and Managing Partner

As the founder of Aventis Advisors, Marcin has more than 20 years of experience in M&A and Corporate Finance. He specializes in the Technology sector with a particular focus on Software, IT Services as well as Business Services. During his career, he’s advised dozens of entrepreneurs and investors. Marcin is passionate about working with diverse people and learning the fascinating histories of founders. It’s all about connecting the world of business and finance, the creativity that goes into structuring deals (as each deal is unique), and developing meaningful connections between people worldwide.

Frequently asked questions

Testing laboratory deals with a disclosed multiple have a median of about 10.1x EBITDA (24 deals) and 2.4x revenue (72 deals). The value of a specific laboratory depends on what it tests, its accreditation scope, its share of recurring samples, its margins and its size. The way to establish it is to put the business in front of several buyers at once, in a sale process run for you.

Laboratories sell for more of their revenue: a median of 2.4x revenue, against 1.6x for inspection companies, at a similar multiple of EBITDA. That points to higher margins in laboratory work, where instruments, accredited methods and turnaround drive the business.

Calibration laboratories: private equity firms or their platforms made 69% of the 187 calibration laboratory deals since 2015, and 75% of those since 2021. Construction materials and pharmaceutical testing laboratories follow, at 59% and 53%, while food, EMC and consumer product laboratories mostly sell to trade buyers.

Private equity firms and their platforms made 42% of the 1,271 laboratory deals since 2015 and 48% of those since 2021. The most frequent buyers are Eurofins Scientific (205 laboratory deals), Trescal (65), Tentamus Group (62), SGS (61) and ALS Limited (34).

Yes, as long as it tests those samples in its own laboratory. Firms whose main work is done at the customer’s site, such as stack testing crews, asbestos surveyors, legionella services, field construction testing and on-site calibration, are excluded, even when they send samples to a laboratory. They are covered on our inspection company valuation pages.

Accreditation is held by the legal entity, so a sale of shares usually keeps it in place, while a sale of assets usually needs a new application. Accreditation bodies expect to be told about a change of ownership or key personnel and may assess the laboratory again. Check what your accreditation body requires before you agree the structure of a deal.

Most laboratories are bought privately, and the parties usually keep the terms confidential. Of 1,271 deals since 2015, 128 disclose a value and 24 disclose enough to calculate an EV/EBITDA multiple, mostly larger transactions involving listed buyers or sellers. The medians on this page are a starting point for a smaller laboratory, and the range for a specific business has to be built from its own figures.

Most of what moves the multiple takes a year or more to build: a broad accreditation scope and a record of recurring, regulated samples. Owners who start two years out choose the timing of their sale. A valuation assessment now shows which of those levers matters for your laboratory.

Yes. An offer from one buyer is priced without competition. We run a competitive sale process for you: we approach the laboratory groups and private equity platforms with a real reason to want your laboratory, bring their offers to one deadline on the same information, and negotiate the price and terms through to closing, so you choose between the best offers, including the first. Talk to us before you reply to the buyer.

A run process is confidential. Buyers sign a confidentiality agreement before they see the laboratory’s name or numbers, and staff and customers are told at the point you choose.

Contact Us

Tell us about what you want to achieve; we can support you from start to close on your M&A journey.